NOVKAN — Novakand Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK5.40m
- -SEK10.67m
Brief: Kancera To Receive About SEK 18 Mln Through Redemption Of Warrants To4
Brief: Kancera Starts Study In COVID-19 Patients
Brief: Kancera Q2 Operating Loss Widens To SEK 13.9 Million
Brief: Kancera: Drug Candidate KAND567 Gives Positive Effect On Movement Ability In Preclinical Model Of Spinal Cord Injury
Brief: Kancera Q1 Operating Loss Widens To SEK 11.1 Mln
Brief: Kancera Applies For New Patent For Drug Candidates KAND567 And KAND145
Brief: Kancera Announces Results Of New Issue
Brief: Kancera AB Resolves Rights Issue Of 157.4 Million Units
Brief: Kancera Reports Positive Results From Final Part Of Phase Ib Program For KAND567
Brief: Kancera Q4 Operating Loss Narrows To SEK 7.5 Million
Brief: Kancera Receives Approval From Fimea And Etisk Kommittee To Start Last Phase Of Ib-Program For KAND567
Brief: Kancera AB Q3 Operating Loss Narrows To SEK 7.5 Million
Brief: Kancera AB Revises Patent Strategy For Hdac-Project With Partner
Brief: Kancera Proposes Rights Issue Of SEK 61.4 Million
Brief: Kancera Presents New Research Results Concerning KAND567
Brief: Kancera Q2 Operating Loss Widens To SEK 12.7 Million
Brief: Kancera To Carry Out New Issue Of 5 Mln Shares
Swedish stocks: Seen opening higher in line with Europe
Brief: Kancera Q1 Operating Loss Narrows To SEK 7.9 Million